VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), through its wholly owned private Peruvian subsidiary, Sombrero Minerales SAC, is pleased to announce that, having completed all required environmental studies, it has formally submitted an Environmental Impact Assessment – Semi-detailed ("EIA-Sd") drill permit application (the "Application") for its Sombrero Project in Peru. The permit, once granted, will ...

Core Points - Mike Lindell Media Corp. has recruited Heather Mullins as the Chief Pentagon Correspondent, enhancing its news division [1][3] - Mullins has a strong military background and extensive experience in election integrity reporting, which aligns with the company's focus [2][3] - The company aims to provide unbiased coverage from the Pentagon, alongside its existing reporting from the White House and Capitol Hill [3][4] Company Overview - Mike Lindell Media Corp. operates a conservative broadcast network, providing an alternative to mainstream media through its platforms, LindellTV and VOCL [4] - The company has grown to serve over 7 million monthly viewers and has recently gained press access to White House events [4] - LindellTV was rebranded from frankspeech.com in February 2025, and VOCL was rebranded from FrankSocial in September 2024 [4] Personnel and Expertise - Heather Mullins has a background in investigative journalism, particularly in election integrity, and has previously contributed to various media outlets [3] - Mullins expressed her honor in joining LindellTV, emphasizing her commitment to serving the military and the country through journalism [2][3] - Mike Lindell, the CEO, highlighted Mullins as a tremendous asset to the company, expecting her to deliver significant stories from the Pentagon [3]

Core Insights - Enerflex Ltd. has appointed Ms. Céline Gerson to its Board of Directors, effective immediately [1] - Ms. Gerson brings 25 years of experience from Fortune 500 companies, enhancing the Board's skillset as Enerflex pursues its strategic goals [2] - Ms. Gerson expressed her enthusiasm for joining Enerflex at a pivotal time, emphasizing the company's commitment to sustainable shareholder value [3] About Céline Gerson - Ms. Gerson has a strong background in international business, strategy development, and commercial positioning, currently serving as President and Group Director for Fugro Americas [3][4] - She holds a B.B.A in International Finance and Marketing and a J.D., along with an Executive Leadership Development program from Harvard Business School [4] About Enerflex - Enerflex is a global provider of energy infrastructure and transition solutions, focusing on natural gas and sustainability [5] - The company employs over 4,400 professionals dedicated to transforming energy for a sustainable future [5] - Enerflex's shares are traded on the Toronto Stock Exchange and the New York Stock Exchange under the symbols "EFX" and "EFXT," respectively [6]

Core Insights - RecycLiCo Battery Materials Inc. announced the retirement of Andris Kikauka from its Board of Directors, who will continue as a consultant to support the management of the company's legacy mining assets [1][2][3] - Mr. Kikauka's consulting role will involve day-to-day advisory responsibilities, ensuring continuity in oversight, regulatory compliance, and strategic planning for the mining portfolio [2] - The company emphasizes the importance of Mr. Kikauka's experience and institutional knowledge as it advances the commercialization of its critical materials recovery technologies [2][3] Company Overview - RecycLiCo specializes in critical minerals refining and lithium-ion battery upcycling, utilizing advanced hydrometallurgical technologies to process mined ore and recover materials [4] - The company's processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage and industrial applications [4] - RecycLiCo's business aligns with the global demand for responsible supply chains and the movement towards strengthening domestic sourcing of critical materials [4]

Core Viewpoint - Alvotech has received approval from the European Commission for AVT03 as a biosimilar to Prolia and Xgeva, which is expected to enhance access to treatments for osteoporosis and cancer-related skeletal issues in Europe [1][4][5]. Company Summary - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space by providing high-quality, cost-effective products [11]. - The approval of AVT03 reflects Alvotech's strong end-to-end platform and its commitment to delivering affordable medicines to patients [4][5]. - Alvotech has established strategic partnerships for the commercialization of AVT03 in Europe, collaborating with STADA and Dr. Reddy's, each holding semi-exclusive rights in various regions [7][12]. Product Summary - AVT03 is approved in two forms: as a 60 mg/mL single-use pre-filled syringe for osteoporosis treatment and as a 70 mg/mL single-use vial for preventing skeletal-related events in cancer patients [3][9]. - The European denosumab market is valued at approximately US$1.2 billion, indicating a significant opportunity for AVT03 to capture market share [2]. - The approval was based on comprehensive evidence, including pharmacokinetic and pharmacodynamic data, and clinical studies demonstrating equivalent efficacy and safety compared to the reference products [8]. Market Context - Osteoporosis-related disabilities in Europe surpass those caused by common cancers, highlighting the importance of effective treatments [6]. - The economic burden of fragility fractures in Europe was estimated at €57 billion in 2019, underscoring the need for cost-effective treatment options like biosimilars [6][7].

Core Insights - OVHcloud has signed a cloud hosting agreement with LCH SA to enhance operational resilience, security, scalability, and faster deployment of services [1][2] - The migration of LCH SA's services to a SecNumCloud qualified environment marks a significant step in its digital transformation [2] - OVHcloud's SecNumCloud solution allows LCH SA to utilize advanced cloud technology while ensuring high security and regulatory compliance [3] Company Overview - OVHcloud is recognized as a global cloud player and the leader in the European cloud market [1] - LCH SA is a key provider of market infrastructure in Europe and plays a significant role in the global financial community [3] Strategic Implications - The collaboration supports LCH SA's fast-growing, diversified global activities across various asset classes [2] - The use of OVHcloud's services is expected to enhance operational efficiency and scalability for LCH SA [3]

Core Insights - Lotus Technology Inc. reported its unaudited financial results for Q3 and the first nine months of 2025, highlighting a challenging transitional period impacted by tariffs and inventory adjustments [1][2][3] Operating Highlights - Total deliveries for the first nine months of 2025 reached 4,612 units, a significant decrease of 40% compared to 7,673 units in the same period of 2024 [5] - Deliveries were primarily driven by China and Europe, with China outpacing the premium auto segment, indicating strong competitive positioning [3][6] - The gross margin improved to 8% in Q3 2025, up from 3% in Q3 2024, attributed to a higher share of upgraded models in total deliveries [3][15] Financial Performance - Total revenue for the first nine months of 2025 was $356 million, down 46% from $653 million in the same period of 2024 [9] - The net loss narrowed by approximately 68% in Q3 and 43% for the nine-month period, indicating improved financial health [8][13] - Key financial results for Q3 2025 included revenue of $137 million, a 46% decrease year-over-year, and a net loss of $65 million, a 68% reduction from the previous year [20][15] Model and Regional Deliveries - Deliveries by model type showed a decline in both Lifestyle SUVs and Sedans (down 18%) and Sportscars (down 64%) compared to the previous year [5] - Regional delivery breakdown indicated that China accounted for 46% of total deliveries, while Europe contributed 34% [6] Strategic Developments - The company plans to unveil a new PHEV model soon, which will enhance its electrification strategy and cater to diverse consumer demands [4][11] - The strategic acquisition of Lotus UK is progressing, expected to close in 2026, aimed at integrating operations and enhancing efficiency [6][11]

Core Insights - The 5th International New Materials Industry Conference commenced in Bengbu, Anhui Province, focusing on "New Technology, New Materials, New Future" [1] - The event attracted over 400 participants, including academicians, experts, and industry leaders [1] Group 1: Government and Institutional Support - Congratulatory letters were sent by Liang Yanshun, Secretary of the CPC Anhui Provincial Committee, and Wang Qingxian, Governor of Anhui Province [2] - The opening ceremony featured speeches from notable figures, including Zhou Yuxian, Chairman of China National Building Material Group, and academicians Gan Yong and Jiang Desheng [2] Group 2: Industry Development and Investment - Anhui Province aims to nurture new quality productive forces, with an annual industrial output target of one trillion CNY [3] - During the conference, 162 projects were signed with a total investment of 70.197 billion CNY, including 79 projects worth 25.101 billion CNY to be implemented in Bengbu [3] - The conference included activities focused on "investment promotion and talent introduction," contributing to industrial upgrading [3]

Core Points - BioPorto A/S has completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million in new capital [1][2] - The new shares represent 8.89% of BioPorto's registered share capital prior to the increase [2] - The nominal share capital of BioPorto now amounts to DKK 495,108,887, consisting of 495,108,887 shares [4] Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient outcomes through actionable kidney biomarkers, particularly for Acute Kidney Injury (AKI) [5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and management of AKI, enabling earlier intervention [5] - BioPorto's tests are marketed under various registrations, including CE mark in several countries and FDA clearance for ProNephro AKI™ in the US [5] Trading and Listing - The new shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the company's permanent ISIN code [3] - The new shares carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3] Capital Structure - Following the capital increase, BioPorto's Articles of Association have been updated to reflect the new share capital structure [4] - The company emphasizes its commitment to transparency and provides access to its announcements and relevant information through its investor relations platform [4]

Core Insights - Rakovina Therapeutics has announced significant advancements in its AI-enabled ATR program, showcasing novel ATR/mTOR dual inhibitors designed for brain penetration and efficacy in PTEN-deficient tumor models [1][2][10] Group 1: Discovery and Development - The company presented a poster at the 2025 Society for Neuro-Oncology Annual Meeting detailing the discovery of CNS-penetrating ATR inhibitors that combine ATR and mTOR inhibition, targeting PTEN-deficient tumors [2][4] - The lead molecules were specifically engineered to cross the blood-brain barrier, making them potentially effective against primary brain cancers and those with a high risk of brain metastasis [2][4] Group 2: Efficacy and Mechanism - The AI-discovered ATR/mTOR inhibitors demonstrated over 50% ATR inhibition at 1 µM, showing comparable or superior potency to existing ATR inhibitors like ceralasertib, tuvusertib, and elimusertib [3][7] - These compounds are designed to co-target ATR and mTOR pathways, which are critical for the survival of PTEN-deficient tumors, potentially overcoming resistance mechanisms associated with ATR-only therapies [4][6] Group 3: Clinical Relevance and Future Directions - The pharmacokinetic profiling indicated favorable tolerability and measurable CNS exposure in mice, supporting further evaluation in brain tumor models [8][9] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials, leveraging AI technologies for rapid drug candidate optimization [11][12]